Vivodyne accelerates drug discovery using lab-grown human tissues, robotics, and AI to generate accurate preclinical test data.
Vivodyne has raised $40.0M in total funding. The most recent round was Series A. The last funding was announced in May 2025.
Vivodyne's investors include Khosla Ventures, Bison Ventures, Kairos Ventures, MBX Capital, Lingotto.
Vivodyne is headquartered in San Francisco, United States.
Vivodyne accelerates drug discovery using lab-grown human tissues, robotics, and AI to generate accurate preclinical test data.
Vivodyne is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Vivodyne — Funding & Investors." VCBacked, May 29, 2025, https://www.vcbacked.co/company/vivodyne. Accessed July 19, 2026.
VCBacked. (2025). Vivodyne — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/vivodyne
{{cite web |title=Vivodyne — Funding & Investors |url=https://www.vcbacked.co/company/vivodyne |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated